These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22318438)

  • 1. Hormone therapy for menopausal symptoms.
    Roberts H
    BMJ; 2012 Feb; 344():e815. PubMed ID: 22318438
    [No Abstract]   [Full Text] [Related]  

  • 2. A personal initiative for women's health: to challenge the Women's Health Initiative.
    Genazzani AR; Gambacciani M
    Gynecol Endocrinol; 2002 Aug; 16(4):255-7. PubMed ID: 12396552
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy: need for reappraisal.
    Nath J
    Natl Med J India; 2002; 15(6):346-8. PubMed ID: 12540069
    [No Abstract]   [Full Text] [Related]  

  • 6. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
    Simon JA; Nahum GG; Stanislaw H; Gaines T
    Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women's health. The vanishing promises of hormone replacement.
    Enserink M
    Science; 2002 Jul; 297(5580):325-6. PubMed ID: 12130763
    [No Abstract]   [Full Text] [Related]  

  • 8. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 9. The missing R.
    Gambacciani M; Genazzani AR
    Gynecol Endocrinol; 2003 Apr; 17(2):91-4. PubMed ID: 12741416
    [No Abstract]   [Full Text] [Related]  

  • 10. The World Health Organization defines hormone replacement therapy as carcinogenic: is this plausible?
    Mueck AO; Seeger H
    Gynecol Endocrinol; 2008 Mar; 24(3):129-32. PubMed ID: 18335326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational studies and clinical trials of menopausal hormone therapy: can they both be right?
    Allison MA; Manson JE
    Menopause; 2006; 13(1):1-3. PubMed ID: 16607089
    [No Abstract]   [Full Text] [Related]  

  • 12. Timing of hormone therapy influences breast cancer risk.
    Harv Womens Health Watch; 2011 Apr; 18(8):7. PubMed ID: 21544975
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comments on the Women's Health Initiative (WHI) and the Million Women Study (MWS) which question the usefulness of hormone substitution during menopause].
    Lopes P
    J Gynecol Obstet Biol Reprod (Paris); 2003 Oct; 32(6):500-2. PubMed ID: 14593295
    [No Abstract]   [Full Text] [Related]  

  • 14. Women's health after WHI.
    Kenemans P
    Maturitas; 2005 May; 51(1):1-3. PubMed ID: 15883101
    [No Abstract]   [Full Text] [Related]  

  • 15. The view of The International Menopause Society on the Women's Health Initiative.
    Schneider HP;
    Climacteric; 2002 Sep; 5(3):211-6. PubMed ID: 12419078
    [No Abstract]   [Full Text] [Related]  

  • 16. Menopausal hormone replacement therapy.
    Varner RE
    Curr Womens Health Rep; 2003 Oct; 3(5):410-7. PubMed ID: 12959701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F; Taylor HS; Karas R; Brinton E; Newman I; Clarkson TB; Mendelsohn M; Lobo RA; Judelson DR; Nachtigall LE; Heward CB; Hecht H; Jaff MR; Harman SM;
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C; Reeves G
    Lakartidningen; 2005 Apr 18-24; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.